[1] 何晓全,刘梅林.中国冠心病防治策略[J].中国全科医学,2015,18(2):239-240.
[2] 潘扬,丁建东.平均血小板体积与冠心病相关性的研究进展[J].东南大学学报(医学版),2018,37(3):549-552.
[3] KESTENBAUM B,SACHS M C,HOOFNAGLE A N,et al.Fibroblast growth factor-23 and cardiovascular disease in the general population:the Multi-Ethnic Study of Atherosclerosis[J].Circ Heart Fail,2014,7(3):409-417.
[4] LUTSEY P L,ALONSO A,SELVIN E,et al.Fibroblast growth factor-23 and incident coronary heart disease,heart failure,and cardiovascular mortality:the Atherosclerosis Risk in Communities study[J].J Am Heart Assoc,2014,3(3):e000936.
[5] ITOH N,ORNITZ D M.Evolution of the Fgf and Fgfr gene families[J].Trends Genet,2004,20(11):563-569.
[6] ITOH N,ORNITZ D M.Fibroblast growth factors:from molecular evolution to roles in development,metabolism and disease[J].J Biochem,2011,149(2):121-130.
[7] ORNITZ D M,ITOH N.The fibroblast growth factor signaling pathway[J].Wiley Interdiscip Rev Dev Biol,2015,4(3):215-266.
[8] ITOH N,OHTA H,NAKAYAMA Y,et al.Roles of FGF Signals in Heart Development,Health,and Disease[J].Front Cell Dev Biol,2016,4:110.
[9] LEIFHEIT-NESTLER M,HAFFNER D.Paracrine Effects of FGF23 on the Heart[J].Front Endocrinol(Lausanne),2018,9:278.
[10] MOHAMMADI M,OLSEN S K,IBRAHIMI O A.Structural basis for fibroblast growth factor receptor activation[J].Cytokine Growth Factor Rev,2005,16(2):107-137.
[11] KUROSU H,OGAWA Y,MIYOSHI M,et al.Regulation of fibroblast growth factor-23 signaling by klotho[J].J Biol Chem,2006,281(10):6120-6123.
[12] URAKAWA I,YAMAZAKI Y,SHIMADA T,et al.Klotho converts canonical FGF receptor into a specific receptor for FGF23[J].Nature,2006,444(7120):770-774.
[13] GOETZ R,BEENKEN A,IBRAHIMI O A,et al.Molecular insights into the klotho-dependent,endocrine mode of action of fibroblast growth factor 19 subfamily members[J].Mol Cell Biol,2007,27(9):3417-3428.
[14] GOLDFARB M,SCHOORLEMMER J,WILLIAMS A,et al.Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels[J].Neuron,2007,55(3):449-463.
[15] SHIMADA T,HASEGAWA H,YAMAZAKI Y,et al.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis[J].J Bone Miner Res,2004,19(3):429-435.
[16] GATTINENI J,BATES C,TWOMBLEY K,et al.FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1[J].Am J Physiol Renal Physiol,2009,297(2):F282-291.
[17] BEN-DOV I Z,GALITZER H,LAVI-MOSHAYOFF V,et al.The parathyroid is a target organ for FGF23 in rats[J].J Clin Invest,2007,117(12):4003-4008.
[18] FON TACER K,BOOKOUT A L,DING X,et al.Research resource:Comprehensive expression atlas of the fibroblast growth factor system in adult mouse[J].Mol Endocrinol,2010,24(10):2050-2064.
[19] QUARLES L D.Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism[J].Nat Rev Endocrinol,2012,8(5):276-286.
[20] ANDRUKHOVA O,SLAVIC S,ODORFER K I,et al.Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23[J].J Bone Miner Res,2015,30(10):1831-1839.
[21] LEIFHEIT-NESTLER M,GROSSE SIEMER R,FLASBART K,et al.Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease[J].Nephrol Dial Transplant,2016,31(7):1088-1099.
[22] LEIFHEIT-NESTLER M,GRABNER A,HERMANN L,et al.Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats[J].Nephrol Dial Transplant,2017,32(9):1493-1503.
[23] BIENAIMÉ F,AMBOLET A,AUSSILHOU B,et al.Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease[J].J Clin Endocrinol Metab,2018,103(6):2319-2328.
[24] ZANCHI C,LOCATELLI M,BENIGNI A,et al.Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor[J].PLoS One,2013,8(8):e70775.
[25] SPICHTIG D,ZHANG H,MOHEBBI N,et al.Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease[J].Kidney Int,2014,85(6):1340-1350.
[26] NEW S E,AIKAWA E.Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification[J].Circ Res,2011,108(11):1381-1391.
[27] SHARAF EL DIN U A,SALEM M M,ABDULAZIM D O.Vascular calcification:When should we interfere in chronic kidney disease patients and how?[J].World J Nephrol,2016,5(5):398-417.
[28] SAPIR-KOREN R,LIVSHITS G.Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin:the role of fibroblast growth factor 23[J].Biofactors (Oxford,England),2014,40(6):555-568.
[29] HYUN Y Y,KIM H,OH Y K,et al.High fibroblast growth factor 23 is associated with coronary calcification in patients with high adiponectin:analysis from the Korean cohort study for Outcome in patients With Chronic Kidney Disease(KNOW-CKD)study[J].Nephrol Dial Transplant,2019,34(1):123-129.
[30] ZHANG M,YAN J,ZHU M,et al.Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D[J].Ann Clin Lab Sci,2015,45(1):17-22.
[31] ROOS M,LUTZ J,SALMHOFER H,et al.Relation between plasma fibroblast growth factor-23,serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function[J].Clin Endocrinol (Oxf),2008,68(4):660-665.
[32] JIMBO R,SHIMOSAWA T.Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23:A Key Molecule in the Cardiovascular Disease[J].Int J Hypertens,2014,2014:381082.
[33] YILMAZ M I,SONMEZ A,SAGLAM M,et al.FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease[J].Kidney Int,2010,78(7):679-685.
[34] MIRZA M A,LARSSON A,LIND L,et al.Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community[J].Atherosclerosis,2009,205(2):385-390.
[35] XIAO Y,PENG C,HUANG W,et al.Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease[J].PLoS One,2013,8(8):e72545.
[36] HU X,MA X,PAN X,et al.Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels[J].Clin Exp Pharmacol Physiol,2015,42(11):1152-1157.
[37] TAYLOR E N,RIMM E B,STAMPFER M J,et al.Plasma fibroblast growth factor 23,parathyroid hormone,phosphorus,and risk of coronary heart disease[J].Am Heart J,2011,161(5):956-962.
[38] SEIFERT M E,DE LAS FUENTES L,GINSBERG C,et al.Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease[J].Am J Nephrol,2014,39(5):392-399.
[39] GUTIÉRREZ O M,MANNSTADT M,ISAKOVA T,et al.Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis[J].N Engl J Med,2008,359(6):584-592.
[40] FAUL C,AMARAL A P,OSKOUEI B,et al.FGF23 induces left ventricular hypertrophy[J].J Clin Invest,2011,121(11):4393-4408.
[41] GRABNER A,AMARAL ANSEL P,SCHRAMM K,et al.Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy[J].Cell Metab,2015,22(6):1020-1032.
[42] MITSNEFES M M,BETOKO A,SCHNEIDER M F,et al.FGF23 and Left Ventricular Hypertrophy in Children with CKD[J].Clin J Am Soc Nephrol:CJASN,2018,13(1):45-52.
[43] MHATRE K N,WAKULA P,KLEIN O,et al.Crosstalk between FGF23-and angiotensin Ⅱ-mediated Ca(2+) signaling in pathological cardiac hypertrophy[J].Cell Mol Life Sci,2018,75(23):4403-4416.
[44] MANABE I,SHINDO T,NAGAI R.Gene expression in fibroblasts and fibrosis:involvement in cardiac hypertrophy[J].Circ Res,2002,91(12):1103-1113.
[45] DAI B,DAVID V,MARTIN A,et al.A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model[J].PLoS One,2012,7(9):e44161.
[46] ZHOU L,LI Y,ZHOU D,et al.Loss of Klotho contributes to kidney injury by derepression of Wnt/beta-catenin signaling[J].J Am Soc Nephrol:JASN,2013,24(5):771-785.
[47] HAO H,LI X,LI Q,et al.FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin[J].Oncotarget,2016,7(40):64649-64664.
[48] GUO Y,XIAO L,SUN L,et al.Wnt/beta-catenin signaling:a promising new target for fibrosis diseases[J].Physiol Res,2012,61(4):337-346.
[49] LAM A P,GOTTARDI C J.beta-catenin signaling:a novel mediator of fibrosis and potential therapeutic target[J].Curr Opin Rheumatol,2011,23(6):562-567.
[50] TAKEDA N,MANABE I.Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling[J].Int J Inflam,2011,2011:535241.
[51] LEIFHEIT-NESTLER M,KIRCHHOFF F,NESPOR J,et al.Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts[J].Nephrol Dial Transplant,2018,33(10):1722-1734.
[52] FRIELER R A,MORTENSEN R M.Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling[J].Circulation,2015,131(11):1019-1030.
[53] 王国威,贡佳慧,卓琳,等.收缩压异常与肾功能下降不同分期的关系[J].东南大学学报(医学版),2018,37(3):385-390.
[54] FAJOL A,CHEN H,UMBACH A T,et al.Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment[J].FASEB J,2016,30(2):994-1001.
[55] KOVESDY C P,QUARLES L D.FGF23 from bench to bedside[J].Am J Physiol Renal Physiol,2016,310(11):F1168-1174.
[56] AKHABUE E,MONTAG S,REIS J P,et al.FGF23(Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults:The CARDIA Study[J].Hypertension (Dallas,Tex:1979),2018,72(1):70-76.
[57] CAI P,PENG Y,LI L,et al.Fibroblast growth factor 23(FGF23) gene polymorphisms are associated with essential hypertension risk and blood pressure levels in Chinese Han population[J].Clin Exp Hypertens,2018,40(7):680-685.
[58] ALONSO A,MISIALEK J R,ECKFELDT J H,et al.Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation:the Atherosclerosis Risk in Communities study[J].J Am Heart Assoc,2014,3(5):e001082.
[59] MEHTA R,CAI X,LEE J,et al.Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease,From the Chronic Renal Insufficiency Cohort Study[J].JAMA Cardiol,2016,1(5):548-556.
[60] MATHEW J S,SACHS M C,KATZ R,et al.Fibroblast growth factor-23 and incident atrial fibrillation:the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS)[J].Circulation,2014,130(4):298-307.
[61] UNSAL A,KOSE BUDAK S,KOC Y,et al.Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease[J].Kidney Blood Press Res,2012,36(1):55-64.
[62] MORITA H,TAKEDA Y,FUJITA S,et al.Gender Specific Association between Serum Fibroblast Growth Factor 23/alpha-Klotho and Coronary Artery and Aortic Valve Calcification[J].J Atheroscler Thromb,2015,22(12):1338-1346. |
